Among the numerous calorie restriction mimetic drugs tested in mice, Rapamycin stands out as a robust anti-aging agent. Despite its proven efficacy in animal studies and long-term use in humans at higher doses, there is a lack of comprehensive human trials targeting age-related health issues. Conducting more trials would encourage physicians to prescribe Rapamycin off-label for anti-aging purposes. The focus of the trial can vary, but it should include measuring biomarkers of aging and overall health. For instance, ongoing studies on gum disease in older patients and ovarian aging have the potential to provide valuable insights into aging. Other similar studies are either planned or in early stages, showing promise for advancing our understanding of aging processes.
A groundbreaking study named Validating Benefits of Rapamycin for Reproductive Aging Treatment (Vibrant) is exploring the potential of Rapamycin to slow down ovarian aging, delay menopause, extend fertility, and reduce age-related diseases. Initial results suggest a 20% decrease in ovary aging without significant side effects, with participants reporting improvements in various health parameters. By administering a small weekly dose of Rapamycin, ovaries release fewer eggs, offering a promising avenue for enhancing women’s health. Although funding for such studies is challenging due to the drug’s off-patent status, the potential benefits for women are substantial. The rapid aging of ovaries allows for measurable changes within six months, making Rapamycin an attractive option for tackling age-related issues in women.
